| value |
{"case_id":"case_d29bc69e85e9fc98" {"case_id":"case_d29bc69e85e9fc98","confidence":0.32,"corroboration":{"agreement":{"count_score":0.5,"down_count":0,"magnitude_weighted_score":0.5,"majority_direction":"neutral","neutral_count":3,"score":0.5,"up_count":0},"base_score":0.5211,"claim_graph":{"case_signal_families":["filing"],"case_source_domains":["sec.gov"],"claims":[{"agreement_score":0.6,"claim_id":"claim_783236f521753667","conflict":false,"direction":"neutral","evidence_count":3,"family_coverage":1,"quality_score":0.5253,"source_coverage":1,"source_trust":0.97,"statement":"VYNE Therapeutics Inc. filed a Form 4 on April 2, 2026, reporting stock transactions by the Chief Scientific Officer.","strength":0.5948}],"coverage":{"claim_count":1,"conflicting_claims":0,"dominant_claim_id":"claim_783236f521753667","multi_family_claims":0,"multi_source_claims":0},"score":0.3701},"contradiction":{"flags":[],"has_unresolved_conflict":false,"resolved_claims":[],"resolved_count":0,"score":0.0,"unresolved_claims":[],"unresolved_count":0},"contradiction_flags":["single_family_evidence","thin_independent_source_coverage"],"evidence_event_count":3,"high_precision_pass":false,"high_trust_source_coverage":1,"independent_source_coverage":1,"low_trust_source_coverage":0,"score":0.5776,"signal_family_coverage":1,"source_trust":{"avg_score":0.97,"domains":[{"count":3,"domain":"sec.gov","score":0.97,"source":"sec_edgar"}],"high_trust_domains":["sec.gov"],"independent_high_trust_sources":1,"low_trust_domains":[]},"source_trust_score":0.8055},"decision":"monitor","entity_key":"equity:VYNE","evidence_event_count":3,"headline":"VYNE Therapeutics Inc. filed a Form 4 on April 2, 2026, reporting stock transactions by the Chief Scientific Officer.","personal_relevance_score":0.1,"theme_key":"entity_development","why_now":"Signal convergence: VYNE Therapeutics Inc. filed a Form 4 on April 2, 2026, reporting stock transactions by the Chief Scientific Officer. [neutral]"}... |